Page 38 - Read Online

Page 10 of 11 Okaz et al. Rare Dis Orphan Drugs J. 2025;4:24 https://dx.doi.org/10.20517/rdodj.2025.15

15. Lancaster MA, Renner M, Martin C, et al. Cerebral organoids model human brain development and microcephaly. Nature.
2013;501:373-9. DOI
16. Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol.
2020;21:571-84. DOI PubMed PMC
17. Schwank G, Koo B, Sasselli V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis
patients. Cell Stem Cell. 2013;13:653-8. DOI
18. Drost J, Van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature.
2015;521:43-7. DOI
19. Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal
organoids. Nat Med. 2015;21:256-62. DOI
20. Roper J, Tammela T, Akkad A, et al. Colonoscopy-based colorectal cancer modeling in mice with CRISPR–Cas9 genome editing and
organoid transplantation. Nat Protoc. 2018;13:217-34. DOI
21. Kaiser VM, Gonzalez-Cordero A. Organoids-the future of pre-clinical development of AAV gene therapy for CNS disorders. Gene
Therapy. 2025. DOI
22. Na H, Kwon J, Kim S, Ahn J, Kwon O, Chung K. Human pluripotent stem cell-derived retinal organoids: a viable platform for
investigating the efficacy of adeno-associated virus gene therapy. Int J Stem Cells. 2024;17:204-11. DOI
23. Berreur E, Lazzaroni G, Roth C, et al. iPSC-hepatocyte organoids as a novel platform to predict AAV gene therapy efficacy. Mol Ther
Methods Clin Dev. 2025;33:101467. DOI
24. Gilbert Family Foundation Contributes nearly $375 million in partnership with Henry Ford Health to Bring Shirley Ryan AbilityLab to
Detroit and create the Nick Gilbert Neurofibromatosis Research Institute. Available from: https://gilbertfamilyfoundation.org/news-
and-stories/henry-ford-health-shirley-ryan-ability-lab-nick-gilbert-neurofibromatosis-institute/ [accessed 12 August 2025].
25. Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J
Med. 2016;375:2550-60. DOI
26. Gross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a
phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023;25:1883-94. DOI PubMed PMC
27. Li L. Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS. Front Pharmacol.
2024;15:1454418. DOI PubMed PMC
28. Chen AP, Coyne GO, Wolters PL, et al; KOMET study investigators. Efficacy and safety of selumetinib in adults with
neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised,
placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405:2217-30. DOI
29. Moertel CL, Hirbe AC, Shuhaiber HH, et al; for the ReNeu Study Group. ReNeu: a pivotal phase 2b trial of mirdametinib in children
and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). JCO. 2024;42:3016-
3016. DOI
30. Leier A, Bedwell DM, Chen AT, et al. Mutation-directed therapeutics for neurofibromatosis type I. Mol Ther Nucleic Acids.
2020;20:739-53. DOI PubMed PMC
31. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358-
78. DOI PubMed PMC
32. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373-83. DOI PubMed
PMC
33. Tang SN, Salazar-Puerta AI, Heimann MK, et al. Engineered extracellular vesicle-based gene therapy for the treatment of discogenic
back pain. Biomaterials. 2024;308:122562. DOI PubMed PMC
34. Salazar-Puerta AI, Rincon-Benavides MA, Cuellar-Gaviria TZ, et al. Engineered extracellular vesicles derived from dermal fibroblasts
attenuate inflammation in a murine model of acute lung injury. Adv Mater. 2023;35:e2210579. DOI PubMed PMC
35. Rincon-Benavides MA, Cuellar-Gaviria T, Alzate-Correa D, et al. Engineered extracellular vesicles as a therapeutic strategy for
neurofibromatosis type I. Biomedical Engineering Society (BMES) Annual Meeting; 2023 Oct 11-14; Seattle WA. Available from
https://2023bmesannual.eventscribe.net/fsPopup.asp?efp=Sk9RVlVJUUwyMDI3Nw&PresentationID=1315447&rnd=0.4760429&
mode=presInfo [accessed 26 August 2025].
36. Rincon-Benavides MA, Cuellar-Gaviria T, Alzate-Correa D, Powell H, Gallego-Pérez D, Higuita-Castro N. Designed extracellular
vesicles loaded with NF1 nucleic acid as a novel therapeutic strategy for neurofibromatosis type 1. International Nanomedicine and
Drug Delivery Symposium (NanoDDS); 2024 Sep 13-15; Orlando, FL.
37. Ortega-Pineda L, Sunyecz A, Salazar-Puerta AI, et al. Designer extracellular vesicles modulate pro-neuronal cell responses and
improve intracranial retention. Adv Healthc Mater. 2022;11:e2100805. DOI
38. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon
pathway. Science. 2013;339:786-91. DOI PubMed PMC
39. Chen X, Tang X, Xie Y, et al. A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity
and can deliver RNA into cells. Sci Signal. 2025;18:eadk3320. DOI PubMed PMC
40. NF2BioSolutions. Available from https://nf2biosolutions.org/non-viral-gene-delivery-zhou-lab-at-yale-university/ [accessed 12 August
2025].
41. Sharma J, Du M, Wong E, et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1